UF startup iOncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor (ICI) therapy.
The patent, owned by the University of Florida Research Foundation (UFRF) and exclusively licensed to iOncologi, further consolidates the intellectual-property portfolio supporting the company’s UNIFYRs™ (UNiversal Immune FortifYing RNAs) platform — an innovative approach that leverages RNA-driven immune reprogramming to restore and amplify checkpoint inhibitor efficacy across multiple solid-tumor types.
